This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
Is This the Right Time to Keep HSIC Stock in Your Portfolio?
by Zacks Equity Research
Henry Schein is backed by a dental and medical distribution scale, digital dentistry push and acquisitions, but debt and macro headwinds weigh on its outlook.
ALGNNegative Net Change IARTNo Net Change HSICPositive Net Change GMEDNegative Net Change
medical medical-devices
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock
by Zacks Equity Research
MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance.
ALGNNegative Net Change IARTNo Net Change MYGNPositive Net Change GMEDNegative Net Change
medical medical-devices
GMED Growth Drivers After NuVasive and What Q1 Signals
by Moumi Mondal
Globus Medical's Q1 showed margin gains, strong spine and trauma growth, and rising robotics adoption as NuVasive synergies support 2026 targets.
SYKNegative Net Change TFXNegative Net Change GMEDNegative Net Change
medical medical-devices
Company News for May 28, 2026
by Zacks Equity Research
Companies in The News Are: DY, BBWI, PDD, CNC
CNCPositive Net Change DYPositive Net Change PDDNegative Net Change BBWIPositive Net Change
medical retail
Stock Market News for May 28, 2026
by Zacks Equity Research
Wall Street closed mixed on Wednesday, driven by healthcare and consumer stocks.
TXNNegative Net Change NVDANegative Net Change
medical semiconductor
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh
by Moumi Mondal
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.
MYGNPositive Net Change HALONegative Net Change ACADNegative Net Change
medical medical-devices
Best Growth Stocks to Buy for May 28th
by Zacks Equity Research
PBI, CNC and MPC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 28, 2026.
PBIPositive Net Change MPCNegative Net Change CNCPositive Net Change
computers medical oil-energy
Bull of the Day: DaVita Inc. (DVA)
by Benjamin Rains
DaVita has soared over 70% in 2026 to new highs. The dialysis services giant is projected to double its EPS between 2023 and 2027. Even though it's up 3,000% in the past 25 years, DVA trades at value stock levels.
DVANegative Net Change
medical
Eli Lilly Stock Hits Record Highs, Becomes First Pharmaceutical Firm Worth $1 Trillion
by Shaun Pruitt
Eli Lilly (LLY) stock has surged to new record highs of over $1,000 a share, cementing its position as one of the market's most dominant growth stories and the first pharmaceutical firm worth $1 trillion.
LLYPositive Net Change AMZNPositive Net Change AAPLPositive Net Change MSFTNegative Net Change PFEPositive Net Change NVOPositive Net Change AMGNPositive Net Change NVDANegative Net Change
investing large-cap medical pharmaceuticals
Top Analyst Reports for Alphabet, Apple & Micron Technology
by Mark Vickery
Alphabet's AI-driven growth in Search, Cloud and subscriptions is boosting momentum, though spending and legal risks remain in focus.
AAPLPositive Net Change AVBPositive Net Change PEGNegative Net Change MUPositive Net Change SUNegative Net Change CPIXPositive Net Change GOOGLNegative Net Change ASRVPositive Net Change
computers finance internet medical tech-stocks